Home About Us Product BPH Overview Opportunity Contact Us  


ProArc Medical Ltd. is a medical device company established to develop and commercialize non-invasive solutions for the treatment of BPH (Benign Prostatic Hyperplasia), commonly known as enlarged prostate.

ProArc Medical’s ClearRingTM is a minimally invasive device that expands the urethra and positions supporting implants in the enlarged prostate tissue, preventing the tissue from compressing the urethral canal.

The ClearRing is positioned to be the treatment of choice for men with moderate to severe BPH symptoms, who have unsuccessfully tried drug treatment and wish to avoid surgery. Unlike medication that offers poor long term results and significant side effects; surgery that requires anesthesia, hospitalization, a long recovery period and potential adverse effects; and minimally invasive therapies that destroy the prostate tissue; ProArc’s treatment preserves the urethra, offers improved immediate results with minimal adverse effects, and can be performed on an outpatient basis, using only local anesthesia.

The Company has graduated from the Misgav Venture Accelerator, and was funded by The Trendlines Group, an Israeli-based early-stage investment group; Maryland/Israel Trendlines Fund, Columbus Nova, a multi-strategy investment firm managing over $15.0 billion of assets through its own funds and affiliated portfolio companies, US private investors and the Israeli Office of Chief Scientist (OCS).

The Company successfully completed its FIM study in Europe. The trial’s six-month follow-up period has provided extremely promising safety and efficacy data..

  Home | About Us | Products | Opportunity | Contact Us